{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:13:37Z","timestamp":1790741617577,"version":"4.1.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30-CA008748"],"award-info":[{"award-number":["P30-CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS105109-01"],"award-info":[{"award-number":["NS105109-01"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Treatment options for recurrent\/refractory central nervous system (CNS) lymphoma are limited but Bruton\u2019s tyrosine kinase inhibitor ibrutinib has shown promise. To increase efficacy and reduce resistance, ibrutinib was combined with lenalidomide in a preclinical study and rituximab (R2I) in a phase Ib trial with expansion.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Ibrutinib 560 mg (dose level 1) or 840 mg (levels 2\u20134) was administered daily; lenalidomide was dosed on days 1\u201321 at 10 mg (level 1\u2005+\u20052), 15 mg (level 3), or 20 mg (level 4) daily; rituximab 500 mg\/m2 was administered every 28 days. Rituximab was given for 6 cycles, lenalidomide for 12 cycles, and ibrutinib ongoing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>25 patients were enrolled (3 each into dose levels 1\u20133; 6 into level 4; and 10 into the expansion cohort at level 4). The median age was 67 years (range 41\u201385) and the median Eastern Cooperative Oncology Group 1 (range 0\u20132). Patients had a median of 2 prior regimens (range 1\u20135). Common adverse events were thrombocytopenia, rash, and lymphopenia. No aspergillosis or grade 5 toxicities were observed. After 12.8 months of median follow-up, 20\/25 (80%) showed a response with a median time to best response of 60 days (range, 25\u2013615). Median progression-free survival (PFS) was 4.3 months (95% CI: 2.4\u2013not reached) with a PFS12m of 37% (95% CI: 22%\u201363%). Median overall survival has not been reached. Patients with rash during treatment had improved PFS (HR: 0.17, 95% CI: 0.05\u20130.55, P-value\u2005=\u2005.003).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>R2I was tolerated well with high response rates and a short time to best respond. Median PFS was limited but 1\/3 of patients had durable responses &amp;gt;12 months. This trial was registered at www.clinicaltrials.gov (NCT03703167).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/neuonc\/noaf104","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T02:39:20Z","timestamp":1745462360000},"page":"2107-2116","source":"Crossref","is-referenced-by-count":4,"title":["Phase Ib study with expansion of ibrutinib, lenalidomide, and rituximab in patients with relapsed\/refractory central nervous system lymphoma"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4664-670X","authenticated-orcid":false,"given":"Lauren R","family":"Schaff","sequence":"first","affiliation":[{"name":"Department of Neurology, Weill Cornell Medical College , New York, New York ,","place":["USA"]},{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna F","family":"Piotrowski","sequence":"additional","affiliation":[{"name":"Department of Neurology, Weill Cornell Medical College , New York, New York ,","place":["USA"]},{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5854-0251","authenticated-orcid":false,"given":"Elena","family":"Pentsova","sequence":"additional","affiliation":[{"name":"Department of Neurology, Weill Cornell Medical College , New York, New York ,","place":["USA"]},{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor T","family":"Gavrilovic","sequence":"additional","affiliation":[{"name":"Department of Neurology, Weill Cornell Medical College , New York, New York ,","place":["USA"]},{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Weill Cornell Medical College , New York, New York ,","place":["USA"]},{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J","family":"Kaley","sequence":"additional","affiliation":[{"name":"Department of Neurology, Weill Cornell Medical College , New York, New York ,","place":["USA"]},{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venissala","family":"Wongchai","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laleh","family":"Emadi-Paramkouhi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli","family":"Madzsar","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian","family":"Quinn","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Breakey","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah S","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe S","family":"Mendez","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]},{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachna","family":"Malani","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]},{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Nolan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Weill Cornell Medical College , New York, New York ,","place":["USA"]},{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaios","family":"Hatzoglou","sequence":"additional","affiliation":[{"name":"Department of Radiology, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Radiology, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M","family":"DeAngelis","sequence":"additional","affiliation":[{"name":"Department of Neurology, Weill Cornell Medical College , New York, New York ,","place":["USA"]},{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1258-6112","authenticated-orcid":false,"given":"Anne S","family":"Reiner","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine S","family":"Panageas","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine H","family":"Francis","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo K","family":"Mellinghoff","sequence":"additional","affiliation":[{"name":"Department of Neurology, Weill Cornell Medical College , New York, New York ,","place":["USA"]},{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Grommes","sequence":"additional","affiliation":[{"name":"Department of Neurology, Weill Cornell Medical College , New York, New York ,","place":["USA"]},{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"issue":"10","key":"2025091918572014200_CIT0001","doi-asserted-by":"crossref","first-page":"e1027","DOI":"10.1212\/WNL.0000000000008900","article-title":"Management and outcome of primary CNS lymphoma in the modern era: An LOC network study","volume":"94","author":"Houillier","year":"2020","journal-title":"Neurology."},{"issue":"9","key":"2025091918572014200_CIT0002","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/neuonc\/now033","article-title":"Primary CNS lymphoma at first relapse\/progression: Characteristics, management, and outcome of 256 patients from the French LOC network","volume":"18","author":"Langner-Lemercier","year":"2016","journal-title":"Neuro Oncol."},{"issue":"9","key":"2025091918572014200_CIT0003","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma","volume":"7","author":"Grommes","year":"2017","journal-title":"Cancer Discov."},{"issue":"3","key":"2025091918572014200_CIT0004","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/nan.12259","article-title":"Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas","volume":"42","author":"Nakamura","year":"2016","journal-title":"Neuropathol Appl Neurobiol."},{"issue":"13","key":"2025091918572014200_CIT0005","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1158\/1078-0432.CCR-11-0395","article-title":"Primary central nervous system lymphomas: A validation study of array-based comparative genomic hybridization in formalin-fixed paraffin-embedded tumor specimens","volume":"17","author":"Braggio","year":"2011","journal-title":"Clin Cancer Res."},{"issue":"12","key":"2025091918572014200_CIT0006","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","article-title":"Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells","volume":"194","author":"Davis","year":"2001","journal-title":"J Exp Med."},{"issue":"6","key":"2025091918572014200_CIT0007","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","article-title":"Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma","volume":"21","author":"Yang","year":"2012","journal-title":"Cancer Cell."},{"issue":"6","key":"2025091918572014200_CIT0008","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma","volume":"31","author":"Lionakis","year":"2017","journal-title":"Cancer Cell."},{"issue":"4","key":"2025091918572014200_CIT0009","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/annonc\/mdz032","article-title":"Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed\/refractory primary CNS lymphoma or primary intraocular lymphoma: A multicenter prospective \u201cproof of concept\u201d phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)dagger","volume":"30","author":"Ghesquieres","year":"2019","journal-title":"Ann Oncol."},{"issue":"8","key":"2025091918572014200_CIT0010","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-14-2221","article-title":"Combination of lenalidomide and rituximab overcomes rituximab resistance in patients with indolent B-cell and mantle cell lymphomas","volume":"21","author":"Chong","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"5","key":"2025091918572014200_CIT0011","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood-2018-09-875732","article-title":"Phase 1b trial of an ibrutinib-based combination therapy in recurrent\/refractory CNS lymphoma","volume":"133","author":"Grommes","year":"2019","journal-title":"Blood."},{"issue":"1","key":"2025091918572014200_CIT0012","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: A single-centre, open-label, phase 2 trial","volume":"17","author":"Wang","year":"2016","journal-title":"Lancet Oncol."},{"issue":"56","key":"2025091918572014200_CIT0013","doi-asserted-by":"crossref","first-page":"101779","DOI":"10.1016\/j.eclinm.2022.101779","article-title":"The iR(2) regimen (ibrutinib plus lenalidomide and rituximab) for relapsed\/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study","volume":"26","author":"Ramchandren","year":"2023","journal-title":"EClinicalMedicine."},{"issue":"4","key":"2025091918572014200_CIT0014","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1200\/JCO.22.00597","article-title":"Smart start: Rituximab, lenalidomide, and ibrutinib in patients with newly diagnosed large B-cell lymphoma","volume":"41","author":"Westin","year":"2023","journal-title":"J Clin Oncol."},{"issue":"13","key":"2025091918572014200_CIT0015","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1212\/WNL.0000000000012515","article-title":"Rituximab-lenalidomide-ibrutinib combination for relapsed\/refractory primary CNS lymphoma: A case series of the LOC network","volume":"97","author":"Houillier C","year":"2021","journal-title":"Neurology."},{"issue":"22","key":"2025091918572014200_CIT0016","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J Clin Oncol."},{"issue":"6","key":"2025091918572014200_CIT0017","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1177\/0091270009335001","article-title":"Phase I study of oral lenalidomide in patients with refractory metastatic cancer","volume":"49","author":"Dahut","year":"2009","journal-title":"J Clin Pharmacol."},{"issue":"2","key":"2025091918572014200_CIT0018","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/bjh.12351","article-title":"Cerebrospinal fluid penetrance of lenalidomide in meningeal myeloma","volume":"162","author":"Anwer","year":"2013","journal-title":"Br J Haematol."},{"issue":"4","key":"2025091918572014200_CIT0019","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00280-011-1781-y","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates","volume":"69","author":"Muscal","year":"2012","journal-title":"Cancer Chemother Pharmacol."},{"issue":"1","key":"2025091918572014200_CIT0020","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/neuonc\/noaa145","article-title":"Phase I\/II study of tirabrutinib, a second-generation Bruton\u2019s tyrosine kinase inhibitor, in relapsed\/refractory primary central nervous system lymphoma","volume":"23","author":"Narita","year":"2021","journal-title":"Neuro Oncol."},{"issue":"21","key":"2025091918572014200_CIT0021","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood-2018-02-835496","article-title":"Phase 1 study of pomalidomide and dexamethasone for relapsed\/refractory primary CNS or vitreoretinal lymphoma","volume":"132","author":"Tun","year":"2018","journal-title":"Blood."},{"key":"2025091918572014200_CIT0022","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2019.05.024","article-title":"Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II \u201cproof-of-concept\u201d iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network","volume":"117","author":"Soussain","year":"2019","journal-title":"Eur J Cancer."},{"issue":"13","key":"2025091918572014200_CIT0023","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/bloodadvances.2017014845","article-title":"Phase 1 investigation of lenalidomide\/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma","volume":"2","author":"Rubenstein","year":"2018","journal-title":"Blood Adv."},{"issue":"13","key":"2025091918572014200_CIT0024","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1182\/blood.2018891598","article-title":"Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed\/refractory non-germinal center B-cell-like DLBCL","volume":"134","author":"Goy","year":"2019","journal-title":"Blood."},{"issue":"10","key":"2025091918572014200_CIT0025","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1001\/archderm.142.10.1298","article-title":"Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma","volume":"142","author":"Sviggum","year":"2006","journal-title":"Arch Dermatol."},{"issue":"7","key":"2025091918572014200_CIT0026","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/annonc\/mdw158","article-title":"Clinical experience with lenalidomide alone or in combination with rituximab in indolent B-cell and mantle cell lymphomas","volume":"27","author":"Ruan","year":"2016","journal-title":"Ann Oncol."},{"issue":"21","key":"2025091918572014200_CIT0027","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1182\/blood-2016-06-718106","article-title":"Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103","volume":"128","author":"Ujjani","year":"2016","journal-title":"Blood."},{"issue":"13","key":"2025091918572014200_CIT0028","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1158\/1078-0432.CCR-06-2610","article-title":"Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies","volume":"13","author":"Wacker","year":"2007","journal-title":"Clin Cancer Res."},{"issue":"18","key":"2025091918572014200_CIT0029","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1158\/1078-0432.CCR-24-0605","article-title":"A phase II study assessing long-term response to ibrutinib monotherapy in recurrent or refractory CNS lymphoma","volume":"30","author":"Grommes","year":"2024","journal-title":"Clin Cancer Res."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noaf104\/62996133\/noaf104.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/27\/8\/2107\/62996133\/noaf104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/27\/8\/2107\/62996133\/noaf104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T22:57:31Z","timestamp":1758322651000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/27\/8\/2107\/8118898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,4,22]]},"published-print":{"date-parts":[[2025,9,17]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noaf104","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,4,22]]}}}